Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$23 Mln
Revenue (TTM)
$3 Mln
Net Profit (TTM)
$0 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
199
P/B Ratio
0.9
Industry P/E
24.51
EV/EBITDA
14.8
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$0
Face value
--
Shares outstanding
11,574,362
CFO
$-896.75 Mln
EBITDA
$-853.70 Mln
Net Profit
$-951.33 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
TherapeuticsMD (TXMD)
| 22.7 | -11.5 | 22.7 | 116.2 | -18.9 | -50.5 | -39.8 |
|
BSE Sensex*
| -14.8 | -11.3 | -15.4 | -5.2 | 6.9 | 7.6 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
TherapeuticsMD (TXMD)
| 89.5 | -61.5 | -59.7 | -70.2 | -50.0 | -36.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
TherapeuticsMD (TXMD)
|
2.0 | 23.0 | 2.8 | 0.3 | -75.9 | 1.1 | 199 | 0.9 |
| 9.1 | 2,179.2 | 510.2 | 146.9 | 37.2 | 35.6 | 15.5 | 4.6 | |
| 12.7 | 3,812.0 | 3,018.8 | 72.1 | 12.6 | -80 | 54.3 | 86.1 | |
| 171.8 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 74.5 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.0 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.5 | 11,237.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.7 | 2.9 | |
| 23.1 | 11,653.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.3 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 |
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD... and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. Address: 951 Yamato Road, Boca Raton, FL, United States, 33431 Read more
Executive Chairman
Governor Thomas G. Thompson
Executive Chairman
Governor Thomas G. Thompson
Headquarters
Boca Raton, FL
Website
The share price of TherapeuticsMD Inc (TXMD) is $2.00 (NASDAQ) as of 01-Apr-2026 16:26 EDT. TherapeuticsMD Inc (TXMD) has given a return of -18.9% in the last 3 years.
The P/E ratio of TherapeuticsMD Inc (TXMD) is 199.00 times as on 31-Mar-2026, a 712 premium to its peers’ median range of 24.51 times.
The P/B ratio of TherapeuticsMD Inc (TXMD) is 0.89 times as on 31-Mar-2026, a 84 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-4.55
|
0.36
|
|
2023
|
-2.52
|
0.89
|
|
2022
|
0.85
|
2.70
|
|
2021
|
-0.02
|
-0.03
|
|
2020
|
-0.04
|
-0.06
|
The 52-week high and low of TherapeuticsMD Inc (TXMD) are Rs 2.94 and Rs 0.84 as of 02-Apr-2026.
TherapeuticsMD Inc (TXMD) has a market capitalisation of $ 23 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in TherapeuticsMD Inc (TXMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.